CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

The Importance of Technology in Multinational Clinical Research

The Importance of Technology in...

Managing Data in Digital Clinical Trials

Managing Data in Digital Clinical...

Israel-Based Clearmind Medicine Offers First Clinical Center for Alcohol Use Disorder Trial

Israel-Based Clearmind Medicine...

Adagene Offers Clinical Trial Collaboration to Evaluate Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Adagene Offers Clinical Trial...

Outsourcing the Potential Laboratory Services To Ensure Maximum Efficacy of Trials

Outsourcing the Potential Laboratory...

Accessing Sensitive Research Data Via European Genome-Phenome Archive(EGA)

Accessing Sensitive Research Data Via...

Boosting Clinical Cooperation for Improved Efficacy of Clinical Trials

Boosting Clinical Cooperation for...

Clinical Trials Climate in EU to Upsurge in the Future

Clinical Trials Climate in EU to...

The Importance of Technology in Multinational Clinical Research

The Importance of Technology in...

Managing Data in Digital Clinical Trials

Managing Data in Digital Clinical...

Israel-Based Clearmind Medicine Offers First Clinical Center for Alcohol Use Disorder Trial

Israel-Based Clearmind Medicine...

Adagene Offers Clinical Trial Collaboration to Evaluate Roche's Standard-of-Care for First-Line Advanced Liver Cancer

Adagene Offers Clinical Trial...

Outsourcing the Potential Laboratory Services To Ensure Maximum Efficacy of Trials

Outsourcing the Potential Laboratory...

Accessing Sensitive Research Data Via European Genome-Phenome Archive(EGA)

Accessing Sensitive Research Data Via...

Boosting Clinical Cooperation for Improved Efficacy of Clinical Trials

Boosting Clinical Cooperation for...

Clinical Trials Climate in EU to Upsurge in the Future

Clinical Trials Climate in EU to...

Rain Therapeutics and Roche to Jointly Conduct Immunotherapy Trial Solid Tumor Treatment

Life Sciences Review Life Sciences Review | Monday, January 10, 2022
Tweet

Milademetan and Atezolizumab, in combination, will assess the potential for MDM2-checkpoint inhibition in genetically selected patient populations.


FREMONT, CA: Patients benefit from clinical trials because they help researchers find cures and preventative measures in the fight against diseases. It is impossible to discover what works in the laboratory or on animals and what does not in humans until clinical trials are conducted. Rain Therapeutics Inc., a late-stage company developing precision oncology therapeutics, has entered into a clinical supply agreement with Roche to supply atezolizumab, an anti-Programmed Death Ligand-1 (PD-L1) monoclonal antibody.


“We are excited to evaluate the combination of MDM2 inhibition and cancer immunotherapy with milademetan and atezolizumab, and believe it presents a strong mechanistic rationale,” states Avanish Vellanki, co-founder and chief executive officer of Rain. 


 


“We believe the therapeutic index afforded by milademetan will enable synergistic combination with PD-L1 checkpoint inhibition and are excited about the potential for favorable results from the Phase 1 study to support moving into subsequent studies across various MDM2-dependent cancers.”


Milademetan, an oral mouse double minute 2 (MDM2) inhibitor, is being evaluated in clinical trials with atezolizumab to treat patients from genetically distinct populations. Rain will sponsor the anticipated clinical trials under this agreement, while Roche will supply atezolizumab.


A Phase 1 clinical trial will be conducted to assess the safety, tolerability, and efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors who lack cyclin-dependent kinase inhibitor 2A (CDKN2A) but have wildtype p53. CDKN2A encodes the tumor suppressor p14ARF, which acts as an MDM2 inhibitor, and CDKN2A deficiency may result in MDM2-dependent cancers. The Phase 1 clinical trial will begin in the second half of 2022. Additional tumor types may be included in subsequent Phase 2 clinical trials evaluating the combination of milademetan and atezolizumab.


Weekly Brief

loading

  • Top 10 Clinical Trial Services Companies - 2022
  • Top 10 Emerging Clinical Trial Management Companies - 2022
  • Top 10 Clinical Trial Management System Companies - 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/rain-therapeutics-and-roche-to-jointly-conduct-immunotherapy-trial-solid-tumor-treatment-nwid-686.html